\-\ Texto\\:\\ \ \(0\)\
\-\ thyroid\\ gland\\-\\ non\\-tender\\,\\ estimated\\ to\\ be\\ approximately\\ 25\\-30\\ grams\\ in\\ size\\.\\ \\ the\\ contour\\ of\\ the\\ thyroid\\ is\\ irregular\\.\\ \\ no\\ discrete\\ nodules\\ are\\ palpable\\.\\ \\ no\\ cervical\\ lymphadenopathy\\ is\\ appreciated\\.tsh\\-\\ \\<0\\.08\\ \\(ref\\ 0\\.49\\-4\\.67\\)ft4\\-\\ 1\\.30\\ \\(ref\\ 0\\.71\\-1\\.85\\)\ \(0\)\
\-\ treatment\\ options\\:\\ i\\-131\\ ablation\\,\\ thioamides\\ \\(methimazole\\ or\\ propylthiouracil\\,\\ b\\-blockers\\ like\\ propanolol\\,\\ surgery\\ \\(thyroidectomy\\)\\,\\ or\\ close\\ clinical\\ follow\\-up\\ without\\ medical\\ or\\ surgical\\ interventionfollow\\-up\\:\\ nm\\ uptake\\ scans\\ can\\ be\\ performed\\ after\\ a\\ series\\ of\\ hyperthyroid\\ treatment\\ as\\ above\\ to\\ assess\\ effectiveness\\ of\\ treatment\\.\\ \\ if\\ concern\\ is\\ for\\ cold\\ nodules\\,\\ fna\\ can\\ be\\ performed\\ to\\ rule\\ out\\ malignancy\\.\ \(0\)\
\-\ i\\-123\\ 24\\-hour\\ thyroid\\ uptake\\ scan\\ was\\ performed\\.\\ \\ the\\ thyroid\\ gland\\ appears\\ symmetrical\\,\\ in\\ usual\\ shape\\ and\\ location\\.\\ \\ there\\ are\\ four\\ foci\\ of\\ increased\\ radiotracer\\ concentration\\ within\\ the\\ gland\\;\\ one\\ at\\ the\\ level\\ of\\ the\\ isthmus\\ on\\ the\\ right\\,\\ one\\ small\\ focus\\ at\\ the\\ junction\\ of\\ the\\ middle\\ and\\ lower\\ thirds\\ of\\ the\\ right\\ lobe\\,\\ one\\ in\\ the\\ upper\\ left\\ lobe\\ and\\ one\\ in\\ the\\ mid\\-lower\\ half\\ of\\ the\\ left\\ lobe\\.\\ \\ there\\ are\\ no\\ photopenic\\ areas\\ identified\\.\\ \\ the\\ thyroid\\-to\\-background\\ ratio\\ appears\\ normal\\ to\\ increased\\.radioiodine\\ uptake\\:\\ 4\\ hours\\-\\ 6\\%\\ \\(ref\\ 2\\-12\\%\\)\\;\\ 24\\ hours\\-\\ 16\\%\\ \\(ref\\ 12\\-30\\%\\)\ \(0\)\
\-\ toxic\\ multinodular\\ goiter\ \(1\)\
\-\ toxic\\ multinodular\\ goiter\ \(1\)\
\-\ hashimoto\\â\\€\\™s\\ thyroiditis\ \(0\)\
\-\ subacute\\ thyroiditis\ \(5\)\
\-\ iodine\\ deficiency\ \(0\)\
\-\ excessive\\ thyroid\\ hormone\\ ingestion\ \(0\)\
\-\ grave\\â\\€\\™s\\ disease\ \(0\)\
\-\ 48\\ yo\\ woman\\ followed\\ in\\ the\\ internal\\ medicine\\ clinic\\ for\\ abnormal\\ thyroid\\ function\\ tests\\,\\ she\\ is\\ clinically\\ euthyroid\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ref\\:\\ 0\\.09121403323361083\ \(0\)\
\-\ thyroid\\:\\ 0\\.07929764026244628\ \(0\)\
\-\ hours\\-\\:\\ 0\\.06653221452050187\ \(0\)\
\-\ multinodular\\:\\ 0\\.04560701661680541\ \(0\)\
\-\ goiter\\:\\ 0\\.04111866108664169\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.04061532995834983\ \(0\)\
\-\ uptake\\:\\ 0\\.03843377461917976\ \(0\)\
\-\ toxic\\:\\ 0\\.03780268629582022\ \(0\)\
\-\ one\\:\\ 0\\.03495443597450029\ \(0\)\
\-\ gland\\-\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ appreciated\\.tsh\\-\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ ft4\\-\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ 1\\.30\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ thioamides\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ propylthiouracil\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ b\\-blockers\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ propanolol\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ interventionfollow\\-up\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ increased\\.radioiodine\\:\\ 0\\.033266107260250935\ \(0\)\
\-\ thyroid\\-to\\-background\\:\\ 0\\.030650457522288878\ \(0\)\
\-\ \\%\\:\\ 0\\.030087864654279362\ \(0\)\
\-\ euthyroid\\:\\ 0\\.029120400510559957\ \(0\)\
\-\ 0\\.49\\-4\\.67\\:\\ 0\\.02803480778432682\ \(0\)\
\-\ methimazole\\:\\ 0\\.02803480778432682\ \(0\)\
\-\ hyperthyroid\\:\\ 0\\.02803480778432682\ \(0\)\
\-\ gland\\:\\ 0\\.027466933519944673\ \(0\)\
\-\ 12\\-30\\:\\ 0\\.02719275664729207\ \(0\)\
\-\ performed\\:\\ 0\\.026972584881818702\ \(0\)\
\-\ nodules\\:\\ 0\\.026735991437001897\ \(0\)\
\-\ mid\\-lower\\:\\ 0\\.0265047507725979\ \(0\)\
\-\ lobe\\:\\ 0\\.02603009827837963\ \(0\)\
\-\ 25\\-30\\:\\ 0\\.02592305009400447\ \(0\)\
\-\ 0\\.71\\-1\\.85\\:\\ 0\\.02592305009400447\ \(0\)\
\-\ effectiveness\\:\\ 0\\.025419158046364763\ \(0\)\
\-\ 0\\.08\\:\\ 0\\.02457710690933001\ \(0\)\
\-\ nm\\:\\ 0\\.02457710690933001\ \(0\)\
\-\ grams\\:\\ 0\\.024217445853464633\ \(0\)\
\-\ thirds\\:\\ 0\\.024217445853464633\ \(0\)\
\-\ appears\\:\\ 0\\.02400550053431886\ \(0\)\
\-\ 24\\-hour\\:\\ 0\\.02388910103463584\ \(0\)\
\-\ grave\\:\\ 0\\.02388910103463584\ \(0\)\
\-\ isthmus\\:\\ 0\\.023587053081150798\ \(0\)\
\-\ 2\\-12\\:\\ 0\\.023307400356042413\ \(0\)\
\-\ hashimoto\\:\\ 0\\.023307400356042413\ \(0\)\
\-\ i\\-123\\:\\ 0\\.023047049897601087\ \(0\)\
\-\ photopenic\\:\\ 0\\.022803508308402706\ \(0\)\
\-\ i\\-131\\:\\ 0\\.02235904402290692\ \(0\)\
\-\ concentration\\:\\ 0\\.022155016772830407\ \(0\)\
\-\ thyroidectomy\\:\\ 0\\.02196145717136795\ \(0\)\
\-\ fna\\:\\ 0\\.02177734334431349\ \(0\)\
\-\ symmetrical\\:\\ 0\\.020828987011177996\ \(0\)\
\-\ iodine\\:\\ 0\\.020307664979174914\ \(0\)\
\-\ ablation\\:\\ 0\\.020187858570440646\ \(0\)\
\-\ ingestion\\:\\ 0\\.019640001929518012\ \(0\)\
\-\ treatment\\:\\ 0\\.019580569353972305\ \(0\)\
\-\ excessive\\:\\ 0\\.01953936703486835\ \(0\)\
\-\ cold\\:\\ 0\\.01944134633145982\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.019275673506758156\ \(0\)\
\-\ usual\\:\\ 0\\.01881840387727322\ \(0\)\
\-\ estimated\\:\\ 0\\.018657801558711728\ \(0\)\
\-\ discrete\\:\\ 0\\.018579992927758006\ \(0\)\
\-\ s\\:\\ 0\\.018496359751808203\ \(0\)\
\-\ hormone\\:\\ 0\\.018283873624205197\ \(0\)\
\-\ ratio\\:\\ 0\\.017879173509663317\ \(0\)\
\-\ deficiency\\:\\ 0\\.017399342658775595\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.01707569427478531\ \(0\)\
\-\ half\\:\\ 0\\.017024352191555955\ \(0\)\
\-\ tests\\:\\ 0\\.01687438868721817\ \(0\)\
\-\ shape\\:\\ 0\\.016777624798111235\ \(0\)\
\-\ subacute\\:\\ 0\\.016546043868389374\ \(0\)\
\-\ \\(\\:\\ 0\\.016355359839483632\ \(0\)\
\-\ assess\\:\\ 0\\.016161958229483932\ \(0\)\
\-\ series\\:\\ 0\\.016042151820749667\ \(0\)\
\-\ concern\\:\\ 0\\.016042151820749667\ \(0\)\
\-\ 48\\:\\ 0\\.01577656390844099\ \(0\)\
\-\ close\\:\\ 0\\.015740103867264627\ \(0\)\
\-\ options\\:\\ 0\\.015668223886243136\ \(0\)\
\-\ contour\\:\\ 0\\.01563279090379091\ \(0\)\
\-\ medicine\\:\\ 0\\.015295639581768838\ \(0\)\
\-\ \\;\\:\\ 0\\.01528619764869882\ \(0\)\
\-\ radiotracer\\:\\ 0\\.015046055421374329\ \(0\)\
\-\ scans\\:\\ 0\\.015015986856660455\ \(0\)\
\-\ like\\:\\ 0\\.014927192526810663\ \(0\)\
\-\ be\\:\\ 0\\.014918000641629386\ \(0\)\
\-\ can\\:\\ 0\\.014628093226181657\ \(0\)\
\-\ 16\\:\\ 0\\.014591541636182377\ \(0\)\
\-\ focus\\:\\ 0\\.014485979930361976\ \(0\)\
\-\ clinic\\:\\ 0\\.0144087024535939\ \(0\)\
\-\ clinically\\:\\ 0\\.014138166874514215\ \(0\)\
\-\ four\\:\\ 0\\.013998388490814783\ \(0\)\
\-\ foci\\:\\ 0\\.01384159980057753\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.013712207070469485\ \(0\)\
\-\ function\\:\\ 0\\.013670043671985993\ \(0\)\
\-\ junction\\:\\ 0\\.013505948909949241\ \(0\)\
\-\ rule\\:\\ 0\\.01346601642190948\ \(0\)\
\-\ \\)\\:\\ 0\\.013462975322892548\ \(0\)\
\-\ are\\:\\ 0\\.013187251387127567\ \(0\)\
\-\ irregular\\:\\ 0\\.012861685481156149\ \(0\)\
\-\ \\:\\:\\ 0\\.0127955639546113\ \(0\)\
\-\ 24\\:\\ 0\\.012537573511796036\ \(0\)\
\-\ malignancy\\:\\ 0\\.01246071576528874\ \(0\)\
\-\ \\<\\:\\ 0\\.012445530292459588\ \(0\)\
\-\ above\\:\\ 0\\.011818636440104969\ \(0\)\
\-\ middle\\:\\ 0\\.01179305271563184\ \(0\)\
\-\ cervical\\:\\ 0\\.011717326062609919\ \(0\)\
\-\ identified\\:\\ 0\\.011522517136552156\ \(0\)\
\-\ palpable\\:\\ 0\\.011428758651319964\ \(0\)\
\-\ or\\:\\ 0\\.011337993384494802\ \(0\)\
\-\ location\\:\\ 0\\.01124795353548639\ \(0\)\
\-\ areas\\:\\ 0\\.010850366683947421\ \(0\)\
\-\ size\\:\\ 0\\.010810852344825553\ \(0\)\
\-\ followed\\:\\ 0\\.010810852344825553\ \(0\)\
\-\ internal\\:\\ 0\\.010810852344825553\ \(0\)\
\-\ out\\:\\ 0\\.010656807082484968\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.010490705628082046\ \(0\)\
\-\ \\,\\:\\ 0\\.010215474170463675\ \(0\)\
\-\ approximately\\:\\ 0\\.009976671043605974\ \(0\)\
\-\ clinical\\:\\ 0\\.009921923773833979\ \(0\)\
\-\ medical\\:\\ 0\\.009921923773833979\ \(0\)\
\-\ no\\:\\ 0\\.009740877177778889\ \(0\)\
\-\ yo\\:\\ 0\\.00970321329548212\ \(0\)\
\-\ 6\\:\\ 0\\.009630642118395752\ \(0\)\
\-\ there\\:\\ 0\\.009597853256339538\ \(0\)\
\-\ level\\:\\ 0\\.009293920859045027\ \(0\)\
\-\ abnormal\\:\\ 0\\.009196574491754383\ \(0\)\
\-\ she\\:\\ 0\\.009052023175298763\ \(0\)\
\-\ scan\\:\\ 0\\.009027439473331995\ \(0\)\
\-\ 4\\:\\ 0\\.008984799642185076\ \(0\)\
\-\ if\\:\\ 0\\.008749975221813719\ \(0\)\
\-\ at\\:\\ 0\\.008737835115710437\ \(0\)\
\-\ is\\:\\ 0\\.0084874079756185\ \(0\)\
\-\ in\\:\\ 0\\.007950891134721791\ \(0\)\
\-\ increased\\:\\ 0\\.007888621818111908\ \(0\)\
\-\ surgery\\:\\ 0\\.00783018514852934\ \(0\)\
\-\ the\\:\\ 0\\.007825431209639196\ \(0\)\
\-\ upper\\:\\ 0\\.0077814358693159185\ \(0\)\
\-\ without\\:\\ 0\\.007592502514559095\ \(0\)\
\-\ woman\\:\\ 0\\.007448690367882665\ \(0\)\
\-\ small\\:\\ 0\\.0074285859787966745\ \(0\)\
\-\ lower\\:\\ 0\\.007252309695712689\ \(0\)\
\-\ left\\:\\ 0\\.007215888824701243\ \(0\)\
\-\ right\\:\\ 0\\.006804767615927673\ \(0\)\
\-\ surgical\\:\\ 0\\.006778195359439448\ \(0\)\
\-\ after\\:\\ 0\\.006671702651355481\ \(0\)\
\-\ to\\:\\ 0\\.006446311070837528\ \(0\)\
\-\ within\\:\\ 0\\.00615143927692861\ \(0\)\
\-\ for\\:\\ 0\\.005502703008624265\ \(0\)\
\-\ disease\\:\\ 0\\.00527070770270077\ \(0\)\
\-\ normal\\:\\ 0\\.005055141338109815\ \(0\)\
\-\ as\\:\\ 0\\.004877650965638218\ \(0\)\
\-\ was\\:\\ 0\\.003729349140429007\ \(0\)\
\-\ of\\:\\ 0\\.0035170958731468205\ \(0\)\
\-\ on\\:\\ 0\\.002731664197605389\ \(0\)\
\-\ and\\:\\ 0\\.0020378378007420957\ \(0\)\
\-\ a\\:\\ 0\\.0014966030257305709\ \(0\)\
\-\ \\.\\:\\ 0\\.001339605135748916\ \(0\)\
